In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...

Here are some strategies for potentially preventing arthritis: Maintain a Healthy Weight: Many cases of arthritis can be ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

The following is a summary of “Deciding to Attend the Emergency Department: Experiences of Patients With Inflammatory ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

UCB SA (OTCMKTS:UCBJF – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 ...

Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have ...

MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level. Click here for more ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.